Connecticut HB 6669 Disclosure
Gocovri® (Amantadine)

Supernus Pharmaceuticals, Inc. (Supernus) provides the following information to Connecticut prescribers, as required by Connecticut House Bill 6669.

The pricing information below reflects Supernus Wholesale Acquisition Costs ("WAC") for the Supernus product: Gocovri®. The WAC represents published catalogue or list price and may not represent actual transactional prices.

The price a customer pays may vary from the prices listed, depending, for example, on how the customer purchases the product, the availability of discounts, the wholesaler/distributor, or other charges.

WAC for Gocovri®

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
Gocovri® (Amantadine)	17772-0085-60	Oral Capsule Extended Release 24 Hour 68.5 MG	$3,569.39
Gocovri® (Amantadine)	17772-0170-60	Oral Capsule Extended Release 24 Hour 137 MG	$3,569.39

Information on variation efficacy of the drug marketed to different racial and ethnic groups is currently not available.
The list below provides the names of generic prescription drugs in the same Therapeutic Class as the Gocovri®. Note that the drugs listed are not necessarily the generic form of the Gocovri®. Rather, these drugs could be the generic form of a drug in the same Therapeutic Class.

This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.

Generic Prescription Drugs in the Same Therapeutic Class*
DRUG #1 Amantadine HCl

* Source: Generic Prescription Drug Data Extracted from Medi-Span

For purposes of listing the generic prescription drugs above, the Therapeutic Class is derived from Medi-Span

Copyright© 2026 Supernus All rights reserved.
10/15/2026